Results 91 to 100 of about 1,053,987 (300)

Continuous immunotherapy beyond disease progression in patients with advanced non-small cell and small cell lung cancer

Cancer Immunology, Immunotherapy
Background The benefits of continuing immunotherapy beyond disease progression in advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) remain uncertain, along with the specific patient subgroups that may gain the most from this ...
Jing Cheng, Wenwen Kang, Yueying Chen, Luyun Pan, Hedong Han, Tangfeng Lv   +5 more
doaj   +1 more source

Mitochondrial Quality Control and Metabolic Memory Phenomenon Associated with Continued Progression of Diabetic Retinopathy. [PDF]

Int J Mol Sci, 2023
Kowluru RA, Alka K.
europepmc   +1 more source

Strengthening transfers and transitions: sustaining improvement, building capacity (National Strategies) [PDF]

, 2009
"This report highlights that sustainable partnership work between LAs and schools can accelerate pupil progress and that Transfer and Transitions are key drivers for raising standards.

core  

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Stereotactic body radiotherapy for oligoprogression with or without switch of systemic therapy

Clinical and Translational Radiation Oncology
Background: Oligoprogression is defined as cancer progression of a limited number of metastases under active systemic therapy. The role of metastasis-directed therapy, using stereotactic body radiotherapy (SBRT), is controversial as is the continuation ...
Jonas Willmann, Eugenia Vlaskou Badra, Selma Adilovic, Maiwand Ahmadsei, Sebastian M. Christ, Stephanie Tanadini-Lang, Michael Mayinger, Matthias Guckenberger, Nicolaus Andratschke   +8 more
doaj   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Combination treatment with nivolumab and Rigvir of a progressive stage IIC skin melanoma patient

Clinical Case Reports, 2019
A 35‐year‐old male patient was diagnosed with stage IIC skin melanoma that rapidly progressed after surgery. Treatment was continued with radiotherapy, which did not stop further spread of disease and the patient was put on a combination of nivolumab and
Linda Brokāne, Inta Jaunalksne, Andra Tilgase, Evija Olmane, Donatas Petroška, Agnija Rasa, Pēteris Alberts   +6 more
doaj   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Effectiveness of Acceptance and Commitment Therapy Management on Self-Differentiation and Fear of Disease Progression in Patients with Breast Cancer

Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, 2020
BACKGROUND AND OBJECTIVE: Fear of disease progression and rejection of what happened and not being able to distinguish oneself from mental processes cause confusion in mental health.
M Hasannezhad Reskati, SH Hosseini, R Alizadeh-Navaei, S Khosravi, B Mirzaian   +4 more
doaj